IDEXX Laboratories Company Profile (NASDAQ:IDXX)

About IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories logoIDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Veterinary Medical Equipment & Supplies
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:IDXX
  • CUSIP: 45168D10
  • Web:
  • Market Cap: $13.84 billion
  • Outstanding Shares: 87,275,000
Average Prices:
  • 50 Day Moving Avg: $156.99
  • 200 Day Moving Avg: $160.01
  • 52 Week Range: $102.45 - $173.01
  • Trailing P/E Ratio: 54.54
  • Foreward P/E Ratio: 44.79
  • P/E Growth: 2.69
Sales & Book Value:
  • Annual Revenue: $1.86 billion
  • Price / Sales: 7.44
  • Book Value: ($0.99) per share
  • Price / Book: -160.15
  • EBITDA: $467.99 million
  • Net Margins: 14.13%
  • Return on Equity: -473.46%
  • Return on Assets: 16.18%
  • Debt-to-Equity Ratio: -6.98%
  • Current Ratio: 0.92%
  • Quick Ratio: 0.75%
  • Average Volume: 503,045 shs.
  • Beta: 0.48
  • Short Ratio: 4.18

Frequently Asked Questions for IDEXX Laboratories (NASDAQ:IDXX)

What is IDEXX Laboratories' stock symbol?

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

How will IDEXX Laboratories' stock buyback program work?

IDEXX Laboratories declared that its board has approved a stock buyback plan on Sunday, June 4th 2017, which allows the company to repurchase 3,000,000 outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's board believes its stock is undervalued.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) issued its earnings results on Tuesday, August, 1st. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.85 by $0.10. The business had revenue of $508.90 million for the quarter, compared to the consensus estimate of $502.44 million. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The business's revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.74 EPS. View IDEXX Laboratories' Earnings History.

What guidance has IDEXX Laboratories issued on next quarter's earnings?

IDEXX Laboratories issued an update on its FY17 earnings guidance on Tuesday, August, 1st. The company provided earnings per share (EPS) guidance of $3.12-3.22 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.07. The company issued revenue guidance of $1.945-1.965 billion, compared to the consensus revenue estimate of $1.94 billion.

Where is IDEXX Laboratories' stock going? Where will IDEXX Laboratories' stock price be in 2017?

6 brokerages have issued 12 month price objectives for IDEXX Laboratories' shares. Their forecasts range from $118.00 to $200.00. On average, they anticipate IDEXX Laboratories' share price to reach $171.60 in the next year. View Analyst Ratings for IDEXX Laboratories.

What are analysts saying about IDEXX Laboratories stock?

Here are some recent quotes from research analysts about IDEXX Laboratories stock:

  • 1. According to Zacks Investment Research, "IDEXX continues to demonstrate solid growth globally with strong international expansion. Management’s innovation-based global strategy is leading to its CAG Diagnostics growth. Solid organic revenue growth buoys optimism. Moreover, the company recently expanded its cloud technology portfolio by adding rVetLink to it. IDEXX’s last reported first quarter was also impressive with earnings and revenues growing year over year. The raised 2017 EPS guidance is also encouraging. Notably,  over the last six months, the company has been trading above the broader Medical Instruments industry. On the other hand, IDEXX's high dependence on third-party distributors and intense competition continue to pose threats. Moreover, with growing international expansion, the company's Companion Animal Diagnostics business is likely to suffer from adverse currency fluxes. The stock’s overvaluation also remains a concern." (7/19/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: June 13, 2017, 12:32 ET Date and time of production: June 13, 2017, 12:32 ET Target Price / Valuation Methodology: IDEXX Laboratories – IDXX Valuation Framework. Our $180 PT uses a premium ~49x multiple on our 2018 adj. EPS estimate of $3.65 (+17% Y/Y). IDXX’ multiple is a premium to its 10-year median multiple of ~31x forward earnings (and 34x excluding the trough of the Great Recession), though we note the stock has traded north of 35x earnings in 2007, 2015, and since June 2016. Abaxis – ABAX Our $46 price target applies a 4.4x P/S multiple to our FY’18 revenue estimate of $240M and implies a 38x P/E multiple on our FY’18 adj." (6/13/2017)

Who are some of IDEXX Laboratories' key competitors?

Who are IDEXX Laboratories' key executives?

IDEXX Laboratories' management team includes the folowing people:

  • Jonathan W. Ayers, Chairman of the Board, President, Chief Executive Officer
  • Brian P. McKeon, Chief Financial Officer, Executive Vice President, Treasurer
  • Giovani Twigge, Chief Human Resource Officer, Corporate Vice President
  • Jay Mazelsky, Executive Vice President
  • Jacqueline L. Studer, Corporate Vice President, General Counsel, Corporate Secretary
  • William T. End, Lead Independent Director
  • Bruce L. Claflin, Independent Director
  • Stuart M. Essig Ph.D., Independent Director
  • Rebecca M. Henderson Ph.D., Independent Director
  • Daniel M. Junius, Independent Director

Who owns IDEXX Laboratories stock?

IDEXX Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Bath Savings Trust Co (0.04%). Company insiders that own IDEXX Laboratories stock include Barry C Johnson, Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Lawrence D Kingsley, Michael J Phd Williams, Rebecca M Henderson, Thomas Craig and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

Who sold IDEXX Laboratories stock? Who is selling IDEXX Laboratories stock?

IDEXX Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Bath Savings Trust Co. Company insiders that have sold IDEXX Laboratories stock in the last year include Brian P Mckeon, Daniel M Junius, Giovani Twigge, Jonathan W Ayers, Rebecca M Henderson, Thomas Craig and William T End. View Insider Buying and Selling for IDEXX Laboratories.

How do I buy IDEXX Laboratories stock?

Shares of IDEXX Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IDEXX Laboratories' stock price today?

One share of IDEXX Laboratories stock can currently be purchased for approximately $158.55.

MarketBeat Community Rating for IDEXX Laboratories (NASDAQ IDXX)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  167 (Vote Underperform)
Total Votes:  404
MarketBeat's community ratings are surveys of what our community members think about IDEXX Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IDEXX Laboratories (NASDAQ:IDXX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $171.60 (8.23% upside)
Consensus Price Target History for IDEXX Laboratories (NASDAQ:IDXX)
Price Target History for IDEXX Laboratories (NASDAQ:IDXX)
Analysts' Ratings History for IDEXX Laboratories (NASDAQ:IDXX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/6/2017Canaccord GenuityReiterated RatingBuy$180.00N/AView Rating Details
8/23/2017Bank of America CorpUpgradeNeutral -> Buy$175.00LowView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$185.00LowView Rating Details
7/28/2017CL KingUpgradeNeutral -> Buy$200.00MediumView Rating Details
5/31/2017AegisInitiated CoverageSell$118.00LowView Rating Details
2/3/2017Feltl & Co.DowngradeHold -> SellN/AView Rating Details
8/3/2016Northcoast ResearchUpgradeSell -> NeutralN/AView Rating Details
4/13/2016Credit Suisse GroupBoost Price TargetOutperform$80.00 -> $85.00N/AView Rating Details
2/1/2016Piper Jaffray CompaniesReiterated RatingNeutral$73.00 -> $75.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 10/16/2015 forward)


Earnings History for IDEXX Laboratories (NASDAQ:IDXX)
Earnings by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Earnings History by Quarter for IDEXX Laboratories (NASDAQ IDXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017Q2 2017$0.85$0.95$502.44 million$508.90 millionViewListenView Earnings Details
4/28/2017Q1 17$0.61$0.77$455.10 million$462.00 millionViewN/AView Earnings Details
2/2/2017Q416$0.51$0.58$436.07 million$443.00 millionViewListenView Earnings Details
11/1/2016Q316$0.59$0.62$448.60 million$448.30 millionViewListenView Earnings Details
8/2/2016Q216$0.62$0.74$444.83 million$467.00 millionViewListenView Earnings Details
4/29/2016Q116$0.47$0.51$403.48 million$417.55 millionViewListenView Earnings Details
1/29/2016Q415$0.44$0.48$397.39 million$400.00 millionViewListenView Earnings Details
10/28/2015Q315$0.53$0.54$409.33 million$406.00 millionViewListenView Earnings Details
7/30/2015Q215$0.57$0.60$412.57 million$413.30 millionViewListenView Earnings Details
4/28/2015Q115$0.98$0.98$394.38 million$382.00 millionViewN/AView Earnings Details
1/30/2015Q414$0.80$0.95$373.20 million$352.00 millionViewN/AView Earnings Details
10/24/2014Q314$0.90$1.05$371.80 million$384.00 millionViewListenView Earnings Details
7/25/2014Q214$1.06$1.10$385.20 million$390.00 millionViewN/AView Earnings Details
4/25/2014Q114$0.87$0.89$361.58 million$360.20 millionViewListenView Earnings Details
2/4/2014Q413$0.81$0.82$347.08 million$354.10 millionViewN/AView Earnings Details
10/22/2013Q313$0.83$0.86$339.70 million$338.30 millionViewN/AView Earnings Details
7/23/2013Q2 2013$0.97$0.99$356.80 million$352.60 millionViewN/AView Earnings Details
4/23/2013Q1 2013$0.83$0.81$341.06 million$332.10 millionViewN/AView Earnings Details
1/29/2013Q4 2012$0.71$0.78$325.10 million$319.50 millionViewN/AView Earnings Details
10/19/2012$0.73$0.76ViewN/AView Earnings Details
7/20/2012$0.90$0.91ViewN/AView Earnings Details
4/20/2012$0.71$0.72ViewN/AView Earnings Details
1/27/2012$0.63$0.67ViewN/AView Earnings Details
10/21/2011$0.65$0.66ViewN/AView Earnings Details
7/22/2011$0.72$0.83ViewN/AView Earnings Details
4/21/2011$0.59$0.62ViewN/AView Earnings Details
1/28/2011$0.55$0.62ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IDEXX Laboratories (NASDAQ:IDXX)
2017 EPS Consensus Estimate: $2.88
2018 EPS Consensus Estimate: $3.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.59$0.61$0.60
Q2 20173$0.82$0.88$0.85
Q3 20173$0.74$0.75$0.75
Q4 20173$0.67$0.72$0.69
Q1 20181$0.78$0.78$0.78
Q2 20181$1.10$1.10$1.10
Q3 20181$0.83$0.83$0.83
Q4 20181$0.82$0.82$0.82
(Data provided by Zacks Investment Research)


Dividend History for IDEXX Laboratories (NASDAQ:IDXX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IDEXX Laboratories (NASDAQ:IDXX)
Insider Ownership Percentage: 2.77%
Institutional Ownership Percentage: 87.58%
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Insider Trades by Quarter for IDEXX Laboratories (NASDAQ:IDXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/28/2017Jonathan W AyersChairmanSell13,000$150.79$1,960,270.00View SEC Filing  
8/23/2017Rebecca M HendersonDirectorSell5,156$153.29$790,363.24View SEC Filing  
8/22/2017Rebecca M HendersonDirectorSell2,578$152.86$394,073.08View SEC Filing  
8/16/2017Jonathan W AyersChairmanSell58,000$155.00$8,990,000.00View SEC Filing  
8/15/2017Jonathan W AyersCEOSell20,000$154.62$3,092,400.00View SEC Filing  
8/14/2017Jonathan W AyersCEOSell18,000$154.91$2,788,380.00View SEC Filing  
8/9/2017Jonathan W AyersChairmanSell17,000$154.54$2,627,180.00View SEC Filing  
8/8/2017Jonathan W. AyersChairmanSell18,000$155.22$2,793,960.00View SEC Filing  
8/3/2017Lawrence D KingsleyDirectorBuy2,000$151.76$303,520.00View SEC Filing  
5/31/2017Giovani TwiggeInsiderSell2,572$166.90$429,266.80View SEC Filing  
5/30/2017Jonathan W AyersChairmanSell13,000$167.82$2,181,660.00View SEC Filing  
5/22/2017William T EndDirectorSell5,000$162.55$812,750.00View SEC Filing  
5/10/2017Jonathan W AyersChairmanSell27,000$162.69$4,392,630.00View SEC Filing  
5/5/2017Jonathan W. AyersChairmanSell26,000$160.61$4,175,860.00View SEC Filing  
5/4/2017Rebecca M HendersonDirectorSell1,700$159.95$271,915.00View SEC Filing  
3/1/2017Lawrence D KingsleyDirectorBuy1,000$146.48$146,480.00View SEC Filing  
2/22/2017Jonathan W AyersChairmanSell35,000$142.58$4,990,300.00View SEC Filing  
2/8/2017Brian P MckeonVPSell9,924$141.64$1,405,635.36View SEC Filing  
2/8/2017Daniel M JuniusDirectorSell3,000$141.75$425,250.00View SEC Filing  
2/8/2017Jonathan W. AyersChairmanSell36,250$141.63$5,134,087.50View SEC Filing  
11/29/2016Jonathan W AyersChairmanSell27,424$119.77$3,284,572.48View SEC Filing  
11/28/2016Jonathan W AyersCEOSell13,188$119.57$1,576,889.16View SEC Filing  
11/23/2016Thomas CraigDirectorSell8,500$120.06$1,020,510.00View SEC Filing  
11/9/2016Jonathan W. AyersChairmanSell40,000$107.85$4,314,000.00View SEC Filing  
11/8/2016William T EndDirectorSell5,000$109.87$549,350.00View SEC Filing  
8/25/2016Rebecca M HendersonDirectorSell9,924$110.43$1,095,907.32View SEC Filing  
8/15/2016Barry C JohnsonDirectorSell9,924$111.37$1,105,235.88View SEC Filing  
8/8/2016Michael J. Phd WilliamsInsiderSell49,560$108.94$5,399,066.40View SEC Filing  
8/5/2016William T EndDirectorSell5,000$108.50$542,500.00View SEC Filing  
8/4/2016Jonathan W. AyersChairmanSell60,000$107.69$6,461,400.00View SEC Filing  
5/5/2016William T EndDirectorSell4,924$85.87$422,823.88View SEC Filing  
2/24/2016Michael J Phd WilliamsEVPSell2,000$71.93$143,860.00View SEC Filing  
2/9/2016Thomas CraigDirectorSell2,054$69.52$142,794.08View SEC Filing  
2/8/2016Brian P. MckeonCFOSell9,054$69.65$630,611.10View SEC Filing  
11/30/2015Thomas CraigDirectorSell7,000$70.28$491,960.00View SEC Filing  
11/12/2015Rebecca M. HendersonDirectorSell2,300$68.39$157,297.00View SEC Filing  
8/31/2015Thomas CraigDirectorSell800$71.77$57,416.00View SEC Filing  
8/18/2015Michael J. Phd WilliamsEVPSell6,586$78.34$515,947.24View SEC Filing  
8/18/2015Thomas CraigDirectorSell2,900$79.41$230,289.00View SEC Filing  
8/17/2015Jonathan W AyersCEOSell14,799$78.45$1,160,981.55View SEC Filing  
5/18/2015William T EndDirectorSell3,527$134.51$474,416.77View SEC Filing  
3/10/2015William T EndDirectorSell3,500$150.89$528,115.00View SEC Filing  
3/4/2015Johnny D PowersEVPSell6,168$158.49$977,566.32View SEC Filing  
2/17/2015Brian P MckeonCFOSell5,000$156.99$784,950.00View SEC Filing  
2/12/2015Jonathan W AyersCEOSell58,245$155.45$9,054,185.25View SEC Filing  
2/5/2015Rebecca M HendersonDirectorSell2,934$156.27$458,496.18View SEC Filing  
2/4/2015Thomas CraigDirectorSell2,200$157.02$345,444.00View SEC Filing  
1/14/2015Jonathan W AyersCEOSell28,512$157.68$4,495,772.16View SEC Filing  
12/3/2014Jonathan W AyersCEOSell29,000$148.49$4,306,210.00View SEC Filing  
11/13/2014Thomas CraigDirectorSell5,000$152.45$762,250.00View SEC Filing  
11/5/2014Jonathan W AyersCEOSell29,000$143.45$4,160,050.00View SEC Filing  
11/4/2014Johnny D PowersEVPSell1,292$142.70$184,368.40View SEC Filing  
8/13/2014M Anne SzostakDirectorBuy2,000$127.03$254,060.00View SEC Filing  
2/20/2014M Anne SzostakDirectorBuy2,000$126.71$253,420.00View SEC Filing  
2/19/2014Thomas CraigDirectorSell4,800$125.42$602,016.00View SEC Filing  
2/3/2014Jonathan AyersCEOSell81,294$112.46$9,142,323.24View SEC Filing  
11/26/2013Jonathan AyersCEOSell78,178$105.29$8,231,361.62View SEC Filing  
11/22/2013Sophie VandebroekDirectorBuy1,000$107.84$107,840.00View SEC Filing  
11/13/2013Jonathan AyersCEOSell78,178$106.36$8,315,012.08View SEC Filing  
11/4/2013M Anne SzostakDirectorBuy1,000$108.24$108,240.00View SEC Filing  
11/4/2013Michael Phd WilliamsEVPSell6,020$108.19$651,303.80View SEC Filing  
10/31/2013William T EndDirectorSell2,500$108.32$270,800.00View SEC Filing  
10/25/2013Jonathan W AyersCEOSell78,178$104.36$8,158,656.08View SEC Filing  
9/13/2013Johnny PowersEVPSell13,128$96.59$1,268,033.52View SEC Filing  
9/5/2013Michael J Phd WilliamsEVPSell5,162$95.58$493,383.96View SEC Filing  
5/9/2013Ali NaquiVPSell12,961$87.00$1,127,607.00View SEC Filing  
2/4/2013Merilee RainesCFOSell175,929$94.25$16,581,308.25View SEC Filing  
11/13/2012Jonathan W AyersCEOSell15,000$89.92$1,348,800.00View SEC Filing  
9/5/2012Johnny D PowersEVPSell4,000$97.12$388,480.00View SEC Filing  
8/8/2012Merilee RainesCFOSell7,726$88.84$686,377.84View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IDEXX Laboratories (NASDAQ:IDXX)
Latest Headlines for IDEXX Laboratories (NASDAQ:IDXX)
DateHeadline logoHere's Why Investors Should Buy Integra LifeSciences Now - October 16 at 3:29 PM logoHere's Why Investors Should Buy Integra LifeSciences Now - October 16 at 3:29 PM logoHere's Why You Should Buy Thermo Fisher Scientific (TMO) Now - October 16 at 3:29 PM logoNuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval - Nasdaq - October 15 at 12:15 AM logoOPKO Health (OPK) Signs New Agreement with Japan Tobacco - Nasdaq - October 15 at 12:15 AM logoNuVasive's (NUVA) PRECICE System Gets Expanded FDA Approval - October 13 at 7:36 PM logoVeeva Systems (VEEV) Rides High on Commercial Cloud Platform - Nasdaq - October 13 at 1:08 AM logoCryoLife to Buy JOTEC, Preliminary Revenue Result Out for Q3 - Nasdaq - October 13 at 1:08 AM logoDENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay ... - Nasdaq - October 13 at 1:08 AM logoPacific Biosciences, Bluebee Team Up for De Novo Sequencing - Nasdaq - October 10 at 7:11 PM logo5 MedTech Stocks for Stellar Returns in Q3 - Nasdaq - October 10 at 7:11 PM logoPacific Biosciences, Bluebee Team Up for De Novo Sequencing - October 10 at 7:11 PM logo4 Top Growth Picks as MedTech Battle Rages On - October 10 at 7:11 PM logo5 MedTech Stocks for Stellar Returns in Q3 - October 10 at 7:11 PM logoIDEXX Laboratories, Inc. (IDXX) Given Consensus Rating of "Hold" by Analysts - October 8 at 3:07 PM logoIDEXX Laboratories' (IDXX) Buy Rating Reiterated at Canaccord Genuity - October 7 at 7:54 AM logoHologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval - October 7 at 1:17 AM logoQIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm - October 7 at 1:17 AM logoIntegra Rides High on Product Launches, Competition Rife - Nasdaq - October 6 at 8:17 PM logoQIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm - Nasdaq - October 6 at 8:17 PM logoPerkinElmer Hits a 52-Week High: What's Driving the Stock? - Nasdaq - Nasdaq - October 6 at 8:17 PM logoETFs with exposure to IDEXX Laboratories, Inc. : October 6, 2017 - October 6 at 8:17 PM logoIdexx Laboratories Sees RS Rating Rise To 73 - October 5 at 9:17 PM logoIDEXX Laboratories to Release 2017 Third Quarter Financial Results - October 5 at 9:17 PM logoAngioDynamicis' (ANGO) Solero MTA System to Drive Growth - October 5 at 10:22 AM logoHenry Schein to Offer CAS' Fully-Automated Cognivue Device - October 5 at 10:22 AM logoHenry Schein to Offer CAS' Fully-Automated Cognivue Device - October 5 at 10:21 AM logoIntegra Rides High on Product Launches, Competition Rife - October 5 at 10:21 AM logoIDEXX Laboratories, Inc. :IDXX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017 - October 5 at 10:21 AM logoIDEXX Laboratories, Inc. – Value Analysis (NASDAQ:IDXX) : October 4, 2017 - October 4 at 4:35 PM logo Analysts Expect IDEXX Laboratories, Inc. (IDXX) Will Announce Quarterly Sales of $493.63 Million - October 4 at 9:10 AM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : IDXX-US : October 3, 2017 - October 3 at 10:12 AM logoQuest Diagnostics Buys 2 Outreach Labs, Widens Customer Base - October 3 at 10:12 AM logoBoston Scientific's Apama Deal to Boost Electrophysiology Arm - October 3 at 10:12 AM logo Analysts Expect IDEXX Laboratories, Inc. (IDXX) to Post $0.75 EPS - October 2 at 2:20 PM logoAngioDynamics (ANGO) Misses on Earnings & Revenues in Q1 - October 2 at 1:16 PM logoAlign Technology (ALGN) Prospects Bright, Competition Rife - Nasdaq - September 26 at 10:42 AM logoPetMed Express Optimistic on New Orders Amid Stiff Rivalry - Nasdaq - September 26 at 10:42 AM logoOmnicell (OMCL) Gains on Product Launches, Global Expansion - Nasdaq - September 26 at 10:42 AM logoHere's Why You Should Invest in Orthofix International Now - September 26 at 10:42 AM logoSTERIS (STE) Rides on Organic Growth, Stiff Contest a Threat - September 26 at 10:42 AM logoAlign Technology (ALGN) Prospects Bright, Competition Rife - September 25 at 6:20 PM logoAllscripts Rides High on Product Launches Amid Rising Costs - September 25 at 9:55 AM logoHere's Why Investors Should Buy Masimo (MASI) Right Now - Nasdaq - September 22 at 6:51 PM logoBD (BDX) Inks New Deal to Strengthen Foothold in STI Space - Nasdaq - September 22 at 1:50 PM logoHere's Why You Should Invest in IDEXX Laboratories (IDXX) Now - Nasdaq - September 22 at 1:50 PM logoIDEXX Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : IDXX-US : September 22, 2017 - September 22 at 1:50 PM logoMasimo (MASI) Launches Rad-97 CO-Oximeter Post FDA Clearance - Nasdaq - September 19 at 7:50 PM logoVarian Medical (VAR) Releases FDA-Approved Eclipse 15.5 - Nasdaq - September 19 at 7:50 PM logoSurmodics Receives FDA's Approval for PTA Balloon Catheter - Nasdaq - September 19 at 7:50 PM



IDEXX Laboratories (IDXX) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.